Human allograft rejection in humanized mice: A historical perspective

Cellular and Molecular Immunology

Volumn 9, Issue 3, 2012, Pages 225-231

  Brehm, Michael A ^a   Shultz, Leonard D ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

human; immunodeficient mice; transplantation

Indexed keywords

CD14 ANTIGEN; CD2 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DNA DEPENDENT PROTEIN KINASE; INTERLEUKIN 2 RECEPTOR GAMMA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ARTERY GRAFT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL POPULATION; DOUBLE STRANDED DNA BREAK; ENGRAFTMENT; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; HUMANIZED MOUSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET BETA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; RISK FACTOR; SKIN ALLOGRAFT; T CELL DEPLETION; VDJ RECOMBINATION;

ANIMALS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; MICE; MICE, MUTANT STRAINS; MICE, SCID; ORGAN TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH;

MUS; RODENTIA;

EID: 84860871911     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2011.64     Document Type: Review

References (98)

1. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation-howmuch of the promise has been realized? Nat Med 2005; 11: 605-613. (Pubitemid 40868300)
2. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973-981. (Pubitemid 32060253)
3. Heeger PS. T-cell allorecognition and transplant rejection: a summary and update.Am J Transplant 2003; 3: 525-533. (Pubitemid 36612835)
4. Chen G, Dong JH. Individualized immunosuppression: new strategies from pharmacokinetics, pharmacodynamics and pharmacogenomics. Hepatobiliary Pancreat Dis Int 2005; 4: 332-338. (Pubitemid 41207529)
5. Odorico JS, Sollinger HW. Technical and immunosuppressive advances in transplantation for insulin-dependent diabetes mellitus. World J Surg 2002; 26: 194-211. (Pubitemid 36920434)
6. Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5: 874-886.
7. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
8. Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: a literature review. Gen Hosp Psychiatry 2000; 22: 412-424.
9. Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001; 72: S89-S93.
10. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS et al. New reagents on the horizon for immune tolerance. Annu Rev Med 2007; 58: 329-346. (Pubitemid 46706518)
11. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118-130. (Pubitemid 46174859)
12. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983; 301: 527-530. (Pubitemid 13160576)
13. Blunt T, Gell D, Fox M, Taccioli GE, Lehmann AR, Jackson SP et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci USA 1996; 93: 10285-10290. (Pubitemid 26314614)
14. Fulop GM, Phillips RA. The scid mutation in mice causes a general defect in DNA repair. Nature 1990; 347: 479-482.
15. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256-259.
16. Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science 1992; 255: 1137-1141.
17. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632-1639.
18. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M et al. RAG-2- deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68: 855-867.
19. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG- 1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869-877.
20. Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 1990; 248: 1517-1523.
21. Gellert M. V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev Biochem 2002; 71: 101-132.
22. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor c chainnull mice. Blood 2005; 106: 1565-1573. (Pubitemid 41208567)
23. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K et al. NOD/SCID/ cc null mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-3182. (Pubitemid 35217065)
24. Legrand N, WeijerK, Spits H. Experimental models to study development and function of the human immune system in vivo. J Immunol 2006; 176: 2053-2058. (Pubitemid 43201649)
25. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rcnull mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477-6489. (Pubitemid 40663843)
26. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti J-C, Lanzavecchia A et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304: 104-107. (Pubitemid 38451466)
27. van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MCH, de Weger RA, Canninga-van Dijk MR et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG22/2 gammac2/2 double-mutant mice. Blood 2003; 102: 2522-2531. (Pubitemid 37193591)
28. Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 2010; 17: 120-125.
29. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by cc family cytokines. Nat Rev Immunol 2009; 9: 480-490.
30. Brehm MA, Cuthbert A, Yang C, Miller DM, Diiorio P, Laning J et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains ofmice bearing the IL2rcnull mutation. Clin Immunol 2010; 135: 84-98.
31. Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL, Shultz LD. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis 1995; 172: 974-982.
32. Lepus CM, Gibson TF, Gerber SA, Kawikova I, Szczepanik M, Ablamunits V et al. Comparison of Human Fetal Liver, Umbilical Cord Blood, and Adult Blood Hematopoietic Stem Cell Engraftment in NOD-scid/cc2/2, Balb/c-Rag22/2cc2/2, and C.B-17-scid/bg immunodeficient mice. Hum Immunol 2009; 70: 790-802.
33. Shultz LD, Lang PA, Christianson SW, Gott B, Lyons B, Umeda S et al. NOD/LtSz- Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol 2000; 164: 2496-2507. (Pubitemid 30115479)
34. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180-191.
35. Tournoy KG, Depraetere S, Pauwels RA, Leroux-Roels GG. Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice. Clin Exp Immunol 2000; 119: 231-239. (Pubitemid 30064615)
36. Takenaka K, Prasolava TK, Wang JCY, Mortin-Toth SM, Khalouei S, Gan OI et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 2007; 8: 1313-1323. (Pubitemid 350138972)
37. Legrand N, Huntington ND, Nagasawa M, Bakker AQ, Schotte R, Strick-Marchand H et al. Functional CD47/signal regulatory protein alpha (SIRPa) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo. Proc Natl Acad Sci USA 2011; 108: 13224-13229.
38. Strowig T, Rongvaux A, Rathinam C, Takizawa H, Borsotti C, Philbrick W et al. Transgenic expression of human signal regulatory protein alpha in Rag22/2cc 2/2 mice improves engraftment of human hematopoietic cells in humanized mice. Proc Natl Acad Sci USA 2011; 108: 13218-13223.
39. Shultz LD, Pearson T, King M, Giassi L, Carney L, Gott B et al. Humanized NOD/LtSzscid IL2 receptor common gamma chain knockout mice in diabetes research. Ann NY Acad Sci 2007; 1103: 77-89. (Pubitemid 46791104)
40. King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M et al. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 2008; 126: 303-314.
41. King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin- 2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 2009; 157: 104-118.
42. Banuelos SJ, Shultz LD, Greiner DL, Burzenski LM, GottB, Lyons BL et al. Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1nullPrf1null mice. Clin Immunol 2004; 112: 273-283. (Pubitemid 39078703)
43. Yu CI, Gallegos M, Marches F, Zurawski G, Ramilo O, García-Sastre A et al. Broad influenza-specific CD81 T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood 2008; 112: 3671-3678.
44. Racki WJ, Covassin L, Brehm M, Pino S, Ignotz R, Dunn R et al. NOD-scid IL2rcnull mouse model of human skin transplantation and allograft rejection. Transplantation 2010; 89: 527-536.
45. Kumar P, Ban H-S, Kim SS, Wu H, Pearson T, Greiner DL et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134: 577-586.
46. Covassin L, Laning J, Abdi R, Langevin DL, Phillips NE, Shultz LD et al. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rcnull H2- Ab1tm1Gru Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol 2011; 166: 269-280.
47. Hoffmann-Fezer G, Gall C, Zengerle U, Kranz B, Thierfelder S. Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Blood 1993; 81: 3440-3448. (Pubitemid 23172932)
48. Sandhu JS, Gorczynski R, Shpitz B, Gallinger S, Nguyen HP, Hozumi N. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantation 1995; 60: 179-184.
49. Huppes W, Hoffmann-Fezer G. Peripheral blood leukocyte grafts that induce human to mouse graft-vs.-host disease reject allogeneic human skin grafts. Am J Pathol 1995; 147: 1708-1714.
50. Pearson T, Shultz LD, Miller D, King M, Laning J, Fodor W et al. Non-obese diabeticrecombination activating gene-1 (NOD-Rag 1null) interleukin (IL)-2 receptor common gamma chain (IL 2 rcnull) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 2008; 154: 270-284.
51. Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, Brezillon N et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 2009; 6: 5-9.
52. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006; 12: 1316-1322. (Pubitemid 44706935)
53. Brainard D, Seung E, Frahm N, Cariappa A, Bailey C, Hart Wet al. Induction of robust cellular and humoral virus-specific adaptive immune responses in HIV-infected humanized BLT mice. J Virol 2009; 83: 7305-7321.
54. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK et al. Antiretroviral preexposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5: e16.
55. Lee WP, Yaremchuk MJ, Pan YC, Randolph MA, Tan CM, Weiland AJ. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991; 87: 401-411.
56. Alegre ML, Peterson LJ, Jeyarajah DR, Weiser M, Bluestone JA, ThistlethwaiteJR. Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts. J Immunol 1994; 153: 2738-2749. (Pubitemid 24278143)
57. Kawamura T, Niguma T, Fechner JH Jr, Wolber R, Beeskau MA, Hullett DA et al. Chronic human skin graft rejection in severe combined immunodeficient mice engrafted with human PBL from an HLA-presensitized donor. Transplantation 1992; 53: 659-665.
58. Murray AG, Petzelbauer P, Hughes CC, Costa J, Askenase P, Pober JS. Human T-cellmediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. Proc Natl Acad Sci USA 1994; 91: 9146-9150.
59. Murray AG, Schechner JS, Epperson DE, Sultan P, McNiff JM, Hughes CC et al. Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin. Am J Pathol 1998; 153: 627-638. (Pubitemid 28373672)
60. Rayner D, Nelson R, Murray AG. Noncytolytic human lymphocytes injure dermal microvessels in the huPBL-SCID skin graft model. Hum Immunol 2001; 62: 598-606. (Pubitemid 32506177)
61. Sultan P, Schechner JS, McNiff JM, Hochman PS, Hughes CC, Lorber MI et al. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol 1997; 15: 759-762. (Pubitemid 27329478)
62. Mosier DE, Stell KL, Gulizia RJ, Torbett BE, Gilmore GL. Homozygous scid/scid;beige/ beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J Exp Med 1993; 177: 191-194. (Pubitemid 23008099)
63. Roder JC, Helfand SL, Werkmeister J, McGarry R, Beaumont TJ, Duwe A. Oxygen intermediates are triggered early in the cytolytic pathway of human NK cells. Nature 1982; 298: 569-572. (Pubitemid 12038659)
64. Kirkiles-Smith NC, Harding MJ, Shepherd BR, Fader SA, Yi T, Wang Y et al. Development of a humanized mouse model to study the role of macrophages in allograft injury. Transplantation 2009; 87: 189-197.
65. Shiao SL, McNiff JM, Pober JS. Memory T cells and their costimulators in human allograft injury. J Immunol 2005; 175: 4886-4896. (Pubitemid 41456370)
66. De Rosa SC, Herzenberg LA, Herzenberg LA, Roederer M. 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat Med 2001; 7: 245-248. (Pubitemid 32148494)
67. Shiao S, Kirkiles-Smith N, Shepherd B, Mcniff J, Carr E, Pober J. Human effector memory CD41 T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol 2007; 179: 4397.
68. Turgeon NA, Banuelos SJ, Shultz LD, Lyons BL, Iwakoshi N, Greiner DL et al. Alloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta2-microglobulin-null mice. Exp Biol Med (Maywood) 2003; 228: 1096-1104. (Pubitemid 37222182)
69. Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wagar EJ, Schweitzer IB et al. Enhanced human CD41 T cell engraftment in beta2-microglobulin- deficient NODscid mice. J Immunol 1997; 158: 3578-3586. (Pubitemid 127488709)
70. Wagar EJ, Cromwell MA, Shultz LD, Woda BA, Sullivan JL, Hesselton RM et al. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol 2000; 165: 518-527. (Pubitemid 30429546)
71. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanizedmouse model. Transplantation 2010; 90: 1321-1327.
72. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011; 3: 83ra42.
73. Halban PA, German MS, Kahn SE, Weir GC. Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab 2010; 95: 1034-1043.
74. Naftanel MA, Harlan DM. Pancreatic islet transplantation. PLoS Med 2004; 1: e58; quiz e75.
75. Harlan DM, Rother KI. Islet transplantation as a treatment for diabetes. N Engl J Med 2004; 350: 2104; author reply 2104.
76. Harlan DM, Kenyon NS, Korsgren O, Roep BO. Current advances and travails in islet transplantation. Diabetes 2009; 58: 2175-2184.
77. Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 2004; 114: 877-883. (Pubitemid 39578711)
78. Ricordi C, Strom TB. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol 2004; 4: 259-268. (Pubitemid 38478661)
79. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069. (Pubitemid 40911269)
80. London NJ, Thirdborough SM, Swift SM, Bell PR, James RF. The diabetic 'human reconstituted' severe combined immunodeficient (SCID-hu) mouse: a model for isogeneic, allogeneic, and xenogeneic human islet transplantation. Transplant Proc 1991; 23: 749.
81. Shiroki R, Poindexter NJ, Woodle ES, Hussain MS, Mohanakumar T, Scharp DW. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice. A model for human islet allograft rejection. Transplantation 1994; 57: 1555-1562. (Pubitemid 24191628)
82. Mathew JM, Blomberg B, Ricordi C, Esquenazi V, Miller J. Evaluation of the tolerogenic effects of donor bone marrow cells using a severe combined immunodeficient mouse-human islet transplant model. Hum Immunol 2008; 69: 605-613.
83. Jacobson S, Heuts F, Juarez J, Hultcrantz M, Korsgren O, Svensson M et al. Alloreactivity but failure to reject human islet transplants by humanized Balb/c/ Rag22/2gc2/2 mice. Scand J Immunol 2010; 71: 83-90.
84. Brehm MA, Bortell R, Diiorio P, Leif J, Laning J, Cuthbert A et al. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rcnullIns2Akita mice. Diabetes 2010; 59: 2265-2270.
85. Ron D. Proteotoxicity in the endoplasmic reticulum: lessons from the Akita diabetic mouse. J Clin Invest 2002; 109: 443-445. (Pubitemid 34171773)
86. Mathews CE, Langley SH, Leiter EH. New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation 2002; 73: 1333-1336. (Pubitemid 34454284)
87. Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997; 46: 887-894. (Pubitemid 27188269)
88. Bolzan AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res 2002; 512: 121-134. (Pubitemid 35441051)
89. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387-397. (Pubitemid 32441591)
90. Thomsen M, Galvani S, Canivet C, Kamar N, Bohler T. Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies. Toxicology 2008; 246: 18-23.
91. Lorber MI, Wilson JH, Robert ME, Schechner JS, Kirkiles N, Qian HY et al. Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. Transplantation 1999; 67: 897-903. (Pubitemid 29169137)
92. Koh KP, Wang Y, Yi T, Shiao SL, Lorber MI, Sessa WC et al. T cell-mediated vascular dysfunction of human allografts results from IFN-cdysregulation of NO synthase. J Clin Invest 2004; 114: 846-856. (Pubitemid 39578744)
93. Lebastchi AH, Khan SF, Qin L, LiW, Zhou J, HibinoNet al. Transforming growth factor beta expression by human vascular cells inhibits interferon gamma production and arterial media injury by alloreactive memory T cells. Am J Transplant 2011; 11: 2332-2341.
94. Rao DA, Eid RE, Qin L, Yi T, Kirkiles-Smith NC, Tellides G et al. Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection. J Exp Med 2008; 205: 3145-3158.
95. Wang Y, Ahmad U, Yi T, Zhao L, Lorber MI, Pober JS et al. Alloimmune-mediated vascular remodeling of human coronary artery grafts in immunodeficient mouse recipients is independent of preexisting atherosclerosis. Transplantation 2007; 83: 1501-1505. (Pubitemid 46934074)
96. Feng G, Nadig SN, Backdahl L, Beck S, Francis RS, Schiopu A et al. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci Transl Med 2011; 3: 83ra40.
97. Nadig SN, Wieckiewicz J, Wu DC, Warnecke G, Zhang W, Luo S et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809-813.
98. Willinger T, Rongvaux A, Strowig T, Manz MG, Flavell RA. Improving human hematolymphoid- system mice by cytokine knock-in gene replacement. Trends Immunol 2011; 32: 321-327.